CDK4 inhibitor

DRUG CLASS:

CDK4 inhibitor

News alerts, weekly reports and conference planners

Related drugs:

ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Sensitive: A2 - Guideline CDK4 inhibitor + CDK6 inhibitor Sensitive : A2	CDK4 inhibitor + CDK6 inhibitor Sensitive: A2 - Guideline CDK4 inhibitor + CDK6 inhibitor Sensitive : A2
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	Aromatase inhibitor + CDK4 inhibitor + CDK6 inhibitor Sensitive: A2 - Guideline Aromatase inhibitor + CDK4 inhibitor + CDK6 inhibitor Sensitive : A2	Aromatase inhibitor + CDK4 inhibitor + CDK6 inhibitor Sensitive: A2 - Guideline Aromatase inhibitor + CDK4 inhibitor + CDK6 inhibitor Sensitive : A2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Sensitive: B - Late Trials CDK4 inhibitor + CDK6 inhibitor Sensitive : B	CDK4 inhibitor + CDK6 inhibitor Sensitive: B - Late Trials CDK4 inhibitor + CDK6 inhibitor Sensitive : B
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	PF-06873600 Sensitive: C2 – Inclusion Criteria PF-06873600 Sensitive : C2	PF-06873600 Sensitive: C2 – Inclusion Criteria PF-06873600 Sensitive : C2
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	PF-07220060 Sensitive: C2 – Inclusion Criteria PF-07220060 Sensitive : C2	PF-07220060 Sensitive: C2 – Inclusion Criteria PF-07220060 Sensitive : C2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor + fulvestrant Sensitive: C2 – Inclusion Criteria CDK4 inhibitor + CDK6 inhibitor + fulvestrant Sensitive : C2	CDK4 inhibitor + CDK6 inhibitor + fulvestrant Sensitive: C2 – Inclusion Criteria CDK4 inhibitor + CDK6 inhibitor + fulvestrant Sensitive : C2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	TQB3616 Sensitive: C2 – Inclusion Criteria TQB3616 Sensitive : C2	TQB3616 Sensitive: C2 – Inclusion Criteria TQB3616 Sensitive : C2
HMGB1 positive	Breast Cancer	HMGB1 positive	Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Sensitive : C3	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Sensitive : C3
IGF1R amplification	HER2 Positive Breast Cancer	IGF1R amplification	HER2 Positive Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
ER mutation	HER2 Negative Breast Cancer	ER mutation	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
35-gene signature	Estrogen Receptor Positive Breast Cancer	35-gene signature	Estrogen Receptor Positive Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
ER negative + HER-2 negative	HER2 Negative Breast Cancer	ER negative + HER-2 negative	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
ASXL1 mutation	Estrogen Receptor Positive Breast Cancer	ASXL1 mutation	Estrogen Receptor Positive Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Sensitive : C3	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Sensitive : C3
BRCA2 mutation	Breast Cancer	BRCA2 mutation	Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
RB1 expression	Breast Cancer	RB1 expression	Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Sensitive : C3	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Sensitive : C3
CHEK2 mutation	Breast Cancer	CHEK2 mutation	Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
ATM mutation	Breast Cancer	ATM mutation	Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Sensitive : C3	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Sensitive : C3
HR positive + RB1 mutation	HER2 Negative Breast Cancer	HR positive + RB1 mutation	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
HR positive + MYC amplification	HER2 Negative Breast Cancer	HR positive + MYC amplification	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
HR positive + MYC mutation	HER2 Negative Breast Cancer	HR positive + MYC mutation	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
HR positive + HER-2 underexpression	HER2 Negative Breast Cancer	HR positive + HER-2 underexpression	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
CETN2 overexpression + HR positive	HER2 Negative Breast Cancer	CETN2 overexpression + HR positive	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
CETN2 overexpression + MLH3 overexpression + PCNA overexpression + HR positive	HER2 Negative Breast Cancer	CETN2 overexpression + MLH3 overexpression + PCNA overexpression + HR positive	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
PCNA overexpression + HR positive	HER2 Negative Breast Cancer	PCNA overexpression + HR positive	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
MLH3 overexpression + HR positive	HER2 Negative Breast Cancer	MLH3 overexpression + HR positive	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
TFF3 overexpression + ER positive	HER2 Negative Breast Cancer	TFF3 overexpression + ER positive	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Sensitive : C3	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Sensitive : C3
TFF1 overexpression + ER positive	HER2 Negative Breast Cancer	TFF1 overexpression + ER positive	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Sensitive : C3	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Sensitive : C3
HR positive + HER-2 negative	Male Breast Cancer	HR positive + HER-2 negative	Male Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Sensitive : C3	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Sensitive : C3

CDK4 inhibitor

CDK4 inhibitor

Associations(60)

Associations
(60)